179 related articles for article (PubMed ID: 8993796)
21. Validation of proliferation indices as surrogate endpoint biomarkers.
Alberts DS; Einspahr J; Aickin M; Hixson L; Earnest D; Roe D; Powell M
J Cell Biochem Suppl; 1994; 19():76-83. PubMed ID: 7823609
[TBL] [Abstract][Full Text] [Related]
22. Reliability of rectal epithelial kinetic patterns as an intermediate biomarker of colon cancer.
Anti M; Marra G; Percesepe A; Armelao F; Gasbarrini G
J Cell Biochem Suppl; 1994; 19():68-75. PubMed ID: 7823608
[TBL] [Abstract][Full Text] [Related]
23. Breast cancer chemoprevention trials using the fine-needle aspiration model.
Kimler BF; Fabian CJ; Wallace DD
J Cell Biochem Suppl; 2000; 34():7-12. PubMed ID: 10762008
[TBL] [Abstract][Full Text] [Related]
24. A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity.
Stearns V; Gallagher A; Kleer CG; Singh B; Freedman M; Haddad BR; Isaacs C; Warren R; Brown M; Cullen J; Trock B; Hayes DF
Clin Cancer Res; 2004 Dec; 10(24):8332-40. PubMed ID: 15623610
[TBL] [Abstract][Full Text] [Related]
25. Progress and perspectives in chemoprevention of head and neck cancer.
Wirth LJ; Haddad RI; Posner MR
Expert Rev Anticancer Ther; 2003 Jun; 3(3):339-55. PubMed ID: 12820777
[TBL] [Abstract][Full Text] [Related]
26. Lack of chemoprevention of dietary Agaricus blazei against rat colonic aberrant crypt foci.
Ziliotto L; Barbisan LF; Rodrigues MA
Hum Exp Toxicol; 2008 Jun; 27(6):505-11. PubMed ID: 18784204
[TBL] [Abstract][Full Text] [Related]
27. Lung cancer: chemoprevention and intermediate effect markers.
Tockman MS
IARC Sci Publ; 2001; 154():257-70. PubMed ID: 11220665
[TBL] [Abstract][Full Text] [Related]
28. If there is gold in the labeling index hills, are we digging in the right place?
Aickin M
J Cell Biochem Suppl; 1994; 19():91-3. PubMed ID: 7823611
[TBL] [Abstract][Full Text] [Related]
29. Exposure biomarkers in chemoprevention studies of liver cancer.
Wild CP; Turner PC
IARC Sci Publ; 2001; 154():215-22. PubMed ID: 11220661
[TBL] [Abstract][Full Text] [Related]
30. Biomarkers and surrogacy: relevance to chemoprevention.
Kensler TW; Davidson NE; Groopman JD; Muñoz A
IARC Sci Publ; 2001; 154():27-47. PubMed ID: 11220666
[TBL] [Abstract][Full Text] [Related]
31. The advancement of cancer chemoprevention by revision of clinical trial strategies.
Sharma RA
Panminerva Med; 2002 Mar; 44(1):41-5. PubMed ID: 11887091
[TBL] [Abstract][Full Text] [Related]
32. Colon cancer chemoprevention: clinical development of aspirin as a chemopreventive agent.
Krishnan K; Ruffin MT; Brenner DE
J Cell Biochem Suppl; 1997; 28-29():148-58. PubMed ID: 9589361
[TBL] [Abstract][Full Text] [Related]
33. Identification of a chemoprevention cohort from a population of women at high risk for breast cancer.
Fabian CJ; Kamel S; Zalles C; Kimler BF
J Cell Biochem Suppl; 1996; 25():112-22. PubMed ID: 9027607
[TBL] [Abstract][Full Text] [Related]
34. Biological relevance of adduct detection to the chemoprevention of cancer.
Sharma RA; Farmer PB
Clin Cancer Res; 2004 Aug; 10(15):4901-12. PubMed ID: 15297390
[TBL] [Abstract][Full Text] [Related]
35. Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors.
Reddy BS; Rao CV
J Environ Pathol Toxicol Oncol; 2002; 21(2):155-64. PubMed ID: 12086402
[TBL] [Abstract][Full Text] [Related]
36. Aberrant crypt foci in colon cancer epidemiology.
Khare S; Chaudhary K; Bissonnette M; Carroll R
Methods Mol Biol; 2009; 472():373-86. PubMed ID: 19107443
[TBL] [Abstract][Full Text] [Related]
37. Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer.
Einspahr JG; Nelson MA; Saboda K; Warneke J; Bowden GT; Alberts DS
Clin Cancer Res; 2002 Jan; 8(1):149-55. PubMed ID: 11801552
[TBL] [Abstract][Full Text] [Related]
38. Biomarkers in colorectal cancer.
Owen RW
IARC Sci Publ; 2001; 154():101-11. PubMed ID: 11220650
[TBL] [Abstract][Full Text] [Related]
39. Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention.
Reddy BS
Environ Mol Mutagen; 2004; 44(1):26-35. PubMed ID: 15199544
[TBL] [Abstract][Full Text] [Related]
40. Development of difluoromethyl-ornithine and Bowman-Birk inhibitor as chemopreventive agents by assessment of relevant biomarker modulation: some lessons learned.
Meyskens FL
IARC Sci Publ; 2001; 154():49-55. PubMed ID: 11220668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
